Ganga Pharmaceuticals (539680) H2 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
H2 24/25 earnings summary
1 Sep, 2025Executive summary
Audited financial results for the half and full year ended March 31, 2025, were approved and published, with the statutory auditors issuing an unmodified opinion on the statements.
The company operates solely in the Ayurveda business segment, so no segmental reporting is required.
Financial highlights
Revenue from operations for FY25 was ₹263.74 lakhs, down from ₹273.58 lakhs in FY24.
Net profit for FY25 was ₹7.90 lakhs, up from ₹4.66 lakhs in FY24.
Total income for FY25 was ₹307.33 lakhs, compared to ₹297.53 lakhs in FY24.
Earnings per share (basic) for FY25 stood at ₹0.16, up from ₹0.11 in FY24.
Key financial ratios and metrics
Gross margin improved as expenses decreased to ₹297.86 lakhs in FY25 from ₹291.20 lakhs in FY24.
Share capital remained at ₹483.65 lakhs; reserves and surplus increased to ₹167.36 lakhs from ₹159.48 lakhs.
Cash and cash equivalents rose to ₹30.24 lakhs at FY25 end, up from ₹2.98 lakhs at FY24 end.
Latest events from Ganga Pharmaceuticals
- FY26 revenue and profit rose, equity increased, and auditors gave an unmodified opinion.539680
H2 25/26 - Revenue up, net profit down, equity raised via warrants, and negative operating cash flow.539680H1 25/26
- Stable revenue, improved profit, and strong cash position mark H1 FY25 performance.539680H1 24/25
- Modest profit growth and capital infusion position the company for expansion in a growing Ayurveda market.539680H2 23/24